Veradermics Inc. is a dermatologist-founded, late clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for prevalent aesthetic and dermatological conditions. Its primary focus centers on pattern hair loss, affecting approximately 50 million men and 30 million women in the United States, where current treatments suffer from high dissatisfaction due to slow results, side effects, and inconvenient administration. The company's lead candidate, VDPHL01, represents an oral, non-hormonal, extended-release formulation of minoxidil, originally a hypertension drug noted for hair growth side effects. This proprietary design aims to optimize hair restoration by maximizing plasma concentrations for follicular benefits while minimizing cardiac risks associated with immediate-release versions. Veradermics is advancing VDPHL01 through a registration-directed clinical program, including fully enrolled Phase 2/3 trials in males and ongoing Phase 3 trials in females, targeting FDA approval via a 505(b)(2) New Drug Application. Founded in 2019 and headquartered in New Haven, Connecticut, Veradermics addresses a $9 billion U.S. market opportunity in hair loss treatments, backed by a seasoned team with deep dermatology expertise.